Tibet man attempts self-immolation near monastery in Qinghai

A Tibetan man set himself on fire near a police station in a Tibetan region of northwestern China’s Qinghai province and was immediately taken away by authorities with no word on his condition, sources in India said Thursday, a day after the incident.

The man, known only as Tsering Samdup, or Tsering, self-immolated on Wednesday afternoon in front of a Chinese police station near a Buddhist monastery in Kyegudo (in Chinese, Jiegu), in Yushul (Yushu) Tibetan Autonomous Prefecture in Qinghai, a Tibetan exile source in India told RFA’s Tibetan Service.

“The Tibetan who self-immolated is a very well-educated person. He was immediately taken away by the Chinese police and no one is allowed to meet or inquire about the self-immolator,” the source told RFA.

“There are no particular restrictions in place in Kyegudo at the moment by the Chinese authorities, in order to present a very normal ambience,” the source added.

A report by the Central Tibetan Administration, the Tibetan government in exile in Dharamsala, India, confirmed the time and place of the incident, but added: “verifiable information on the name and background detail of the self-immolator is not available.”

With Wednesday’s incident, 159 Tibetans are confirmed to have set themselves on fire since 2009, mostly to protest Chinese rule in Tibetan areas, and another eight have taken their lives in Nepal and India, home to large exile populations.

The previous known self-immolation took place on Feb. 25, when popular contemporary singer Tsewang Norbu, 25, shouted slogans and set himself on fire in a protest in front of the iconic Potala Palace in the Tibet regional capital Lhasa.

Tsering’s attempt is the first one in Yushul since a spate of six self-immolations by men aged 22 to 62 in 2012.

A region of nomads and monasteries that was part of Tibet’s traditional Kham province, Yushul lies at an altitude of 3,700 m (12,100 ft) in the mountainous eastern edge of the Tibetan plateau.

Sporadic demonstrations challenging Beijing’s rule over what was an independent nation until China’s invasion in 1950 have continued in Tibetan-populated areas of China since widespread protests swept the region in the run-up to the 2008 Beijing Olympics.

High-technology controls on phone and online communications in Tibetan areas often prevent news of Tibetan protests and arrests from reaching the outside world, and sharing news of self-immolations outside China can lead to jail sentences.

Chinese authorities maintain a tight grip on the Himalayan region, restricting Tibetans’ political activities and peaceful expression of ethnic and religious identity, and subjecting Tibetans to persecution, torture, imprisonment, and extrajudicial killings.

Translated by Tenzin Dickyi for RFA’s Tibetan Service. Written in English by Paul Eckert.

Umit Ciftci ได้รับแต่งตั้งให้เป็นผู้จัดการฝ่ายพัฒนาธุรกิจระดับภูมิภาคของตุรกี

เตเมคูลา แคลิฟอร์เนีย, March 31, 2022 (GLOBE NEWSWIRE) — กลุ่มพลังงานสะอาดและก๊าซอุตสาหกรรมของ Nikkiso Cryogenic Industries (“กลุ่มบริษัท”) ซึ่งเป็นส่วนหนึ่งของกลุ่มบริษัท Nikkiso Co., Ltd (ประเทศญี่ปุ่น) มีความยินดีที่จะประกาศว่า Umit Ciftci ได้รับแต่งตั้งให้เป็นผู้จัดการฝ่ายพัฒนาธุรกิจระดับภูมิภาคของตุรกีและพื้นที่โดยรอบ

โดยจะรับผิดชอบสายผลิตภัณฑ์ทั้งหมดของกลุ่ม และจะรายงานต่อ Ole Jensen, NCE&IG GmbH เยอรมนี และจะประจำอยู่ในอิสตันบูล ประเทศตุรกี

Umit ได้รับปริญญาด้านวิศวกรรมการจัดการ ซึ่งทำให้มีพื้นฐานที่แน่นในด้านวิศวกรรม เช่นเดียวกันกับด้านธุรกิจและการเงิน เขามีประสบการณ์มากกว่า 25 ปีในด้านระบบอัดอากาศ และทำงานในตำแหน่งต่าง ๆ ซึ่งได้แก่วิศวกรฝ่ายขาย ผู้จัดการฝ่ายการตลาดและสายธุรกิจในตุรกี อีกทั้งยังทำงานให้กับ Atlas Copco ในสหรัฐอาหรับเอมิเรตส์โดยรับหน้าที่เป็นผู้จัดการฝ่ายพัฒนาธุรกิจ

Ole Jensen รองประธาน NCEIG Europe กล่าวว่า “ประสบการณ์ของ Umit ตลอดจนความรู้ด้านตลาดและอุตสาหกรรมจะเป็นประโยชน์อย่างยิ่งต่อ NCEIG GmbH ในขณะที่เราทำงานเพื่อพัฒนาโอกาสที่เป็นไปได้ในตลาดนี้ เราหวังเป็นอย่างยิ่งว่าเขาจะช่วยทำสิ่งที่ยอดเยี่ยมมากมายให้แก่เรา”

นอกจากนี้ Nikkiso ยังคงมุ่งมั่นที่จะแสดงตัวตนให้เป็นที่ประจักษ์แก่ลูกค้า ทั้งในระดับสากลและระดับท้องถิ่

เกี่ยวกับ CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (โดยปัจจุบันเป็นสมาชิกของ Nikkiso Co., Ltd.) บริษัทสมาชิกได้ผลิตอุปกรณ์แปรรูปก๊าซแช่แข็งเย็นยิ่งยวดทางวิศวกรรมและโรงงานแปรรูปขนาดเล็กสำหรับก๊าซธรรมชาติเหลว (LNG) บริการบ่อน้ำและอุตสาหกรรมก๊าซอุตสาหกรรม Cryogenic Industries ก่อตั้งขึ้นเมื่อ 50 ปีที่แล้ว โดยเป็นบริษัทแม่ของ ACD, Cosmodyne และ Cryoquip และเป็นกลุ่มที่ควบคุมโดยทั่วไปซึ่งมีหน่วยงานปฏิบัติการประมาณ 20 แห่ง

ดูรายละเอียดเพิ่มเติมได้ที่ www.nikkisoCEIG.com และ www.nikkiso.com.

สำหรับการติดต่อด้านสื่อ:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Junshi Biosciences Announces Full Year 2021 Financial Results and Provides Corporate Updates

-Tackling the COVID-19 pandemic challenge with multi-pronged strategies

 Pipeline progressed and expanded substantially

SHANGHAI, China, March 31, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced financial results for the full year 2021 and provided corporate updates.

Full Year 2020 Financial Highlights

  • Total revenue reached RMB 4,025 million in 2021, representing an increase of 152% compared to the year 2020. Revenue from out-licensing significantly increased to RMB3,341 million, which is based on two cooperation projects: 1) the research collaboration and license agreement with Lilly and Company (“Lilly”); 2) the license and commercialization agreement with Coherus BioSciences, Inc. (“Coherus”). Sales of toripalimab was RMB 412 million for the year. The decrease was mainly due to a 60% reduction in reimbursement price of toripalimab in 2021 and the adjustment of the value of wholesalers’ inventories. With a new sales leadership and strategy and additional approved indications, the company is confident that it can gain market share in the approved indications that have been included in NRDL.
  • Total research and development (“R&D”) expenses were RMB2,069 million, representing an increase of 16% compared to the prior year. The increase in R&D expenses was mainly due to: 1) continuous increasing R&D investment, continuous diversification and expansion of product pipelines; 2) the acceleration of the development of existing clinical projects; and 3) expansion of the R&D team and investment in attracting and retaining personnel.
  • Total comprehensive expense was RMB719 million, representing a decrease of 57% compared to the prior year. The decrease was mainly attributable to the increase of revenue from out-licensing, partially offset by the increasing R&D expenses, administrative expenses and selling and distribution expenses.
  • Net cash from financing activities was RMB2,666 million, which was mainly attributable to the successful placing of the company’s new H shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on 23 June 2021 with net cash inflows of RMB2,105 million and receipts of capital contribution from external investors to Shanghai JunTop Biosciences Co., Ltd. (“JunTop Biosciences”), a non-wholly owned subsidiary with net cash inflows of RMB895 million. This cash inflow fully covered the cash used in operating and investing activities, leading to an increase of RMB120 million in cash and cash equivalents.
  • Cash and cash equivalents as of December 31, 2021 were approximately RMB3,505 million. In March 2022, the Board passed a resolution and proposed to issue 70 million A Shares to target subscribers, and the total proceeds are expected to be approximately RMB3,980 million.

Business Highlights

During the year 2021 and 2022 to date, Junshi Biosciences continuously adhered to the strategic plan of “International layout with a base in China,” and has achieved significant growth in operating income, which gradually demonstrated its “income generation” capability. In addition, several of its R&D pipelines have reached key milestones. Junshi has also achieved progress with respect to product commercialization, clinical trials and pipeline expansion, including the following achievements and milestones:

  • Advancement in pipeline: The company’s innovative R&D field has expanded from monoclonal antibodies to the development of more drug modalities, including small molecules, polypeptide drugs, antibody drug conjugates (ADCs), bi-specific or multi-specific antibodies and nucleic acid drugs, as well as the exploration of next-generation innovative therapies for cancer and autoimmune diseases. Product pipelines cover 5 major therapeutic areas including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. There are 3 assets (toripalimab, etesevimab and adalimumab) under commercialization, 23 assets under clinical trials with ongericimab, VV116, bevacizumab, and PARP inhibitor under Phase III clinical trials, and over 25 drug candidates under pre-clinical drug development.
    • In January 2021, toripalimab for the first-line treatment of mucosal melanoma was granted the Fast Track Designation by the United States Food and Drug Administration (the “FDA”). Meanwhile, the FDA also approved the Investigational New Drug (“IND”) application for an immediate Phase III clinical trial of toripalimab in combination with axitinib for the first-line treatment of mucosal melanoma. In March 2021, the indication was granted Breakthrough Therapy Designation (“BTD”) by the National Medical Products Administration of China (the “NMPA”).
    • In February 2021, Junshi Biosciences entered into an Exclusive License and Commercialization Agreement with Coherus. Pursuant to the agreement, the Company granted Coherus an exclusive license for toripalimab and two option programs (if exercised) in the Coherus Territory, as well as the right of first negotiation for two early-stage checkpoint inhibitor antibodies, and may receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments. Coherus made a one-time upfront payment of US$150 million to the Company.
    • In February 2021, the supplemental new drug application (“sNDA”) for toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) was accepted by the NMPA. In November 2021, the indication was approved by the NMPA.
    • In February 2021, the sNDA for toripalimab for the treatment of patients with recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy was granted conditional approval by the NMPA.
    • In January and February 2021, TAB006/JS006 (recombinant humanized anti-TIGIT monoclonal antibody) received IND approval from the NMPA and the FDA, respectively.
    • In February 2021, the IND applications for JS110 (XPO1 inhibitor) and JS111 (EGFR exon20 insertion and other uncommon mutation inhibitor) jointly developed by Junshi Biosciences and Wigen Biomedicine Technology (Shanghai) Co., Ltd. (“Wigen Biomedicine”) were accepted by the NMPA, and the company received IND approvals in April 2021.
    • In February 2021, the IND application for the drug candidate JS201 (anti-PD-1/TGF-β bifunctional fusion protein) was accepted by the NMPA, and the company received IND approval in May 2021.
    • In March 2021, TopAlliance Biosciences, Inc. (“TopAlliance”), the company’s wholly-owned subsidiary, initiated the rolling submission of Biologics License Application (“BLA”) for toripalimab to the FDA for the treatment of recurrent or metastatic NPC, and obtained a rolling review. Toripalimab has become the first domestic anti-PD-1 monoclonal antibody to submit a BLA to the FDA. In August 2021, toripalimab in combination with gemcitabine and cisplatin for the first-line treatment for patients with advanced recurrent or metastatic NPC was granted a BTD by the FDA. In September 2021, the company completed the rolling submission of BLA for the above two indications. At the end of October 2021, BLA for the above two indications was accepted by the FDA. According to the acceptance letter, the FDA has granted priority review designation for the BLA and indicated that it does not plan to hold an advisory committee meeting for the BLA. The Prescription Drug User Fee Act (the “PDUFA”) action date is set on or around April 2022.
    • In March 2021, the IND application for JS103 (pegylated uricase derivative) was accepted by the NMPA, and the company received IND approval in May 2021.
    • In March 2021, the IND application for JS007 (recombinant humanized anti-CTLA-4 monoclonal antibody) was accepted by the NMPA, and the company received IND approval in June 2021.
    • In April 2021, the sNDA for toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma (“UC”) who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy was granted conditional approval by the NMPA.
    • In April 2021, the Independent Data Monitoring Committee (“IDMC”) determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (“ESCC”) had reached its pre-specified primary endpoints of Progression Free Survival (“PFS”) and Overall Survival (“OS”) at the interim analysis of a randomized, double-blind, placebo-controlled, multi-center, Phase III clinical study (“JUPITER-06 study”, NCT03829969).
    • In June 2021, the IND application for JS014 (recombinant IL-21 – a nanobody fusion protein of anti-human serum albumin (HSA)) was accepted by the NMPA, and the company received IND approval in August 2021.
    • In July 2021, the sNDA for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic ESCC was accepted by the NMPA.
    • In August 2021, the IND application for UBP1213sc (recombinant humanized anti-B lymphocyte stimulator (BLyS) monoclonal antibody) was accepted by the NMPA, and the company received IND approval in November 2021.
    • In September 2021, the IND application for JS012 (recombinant humanized anti-Claudin18.2 monoclonal antibody) was accepted by the NMPA. It was later approved in November 2021.
    • In October 2021, the IND application for JS019 (recombinant fully human anti- CD39 monoclonal antibody) jointly developed by Junshi Biosciences and Beijing Eirene Biotech Co., Ltd. (“Beijing Eirene”) was accepted by the NMPA. It was later approved in December 2021.
    • In October 2021, the IND application for JS026 (recombinant fully human monoclonal antibody for treatment of COVID-19) was accepted by the NMPA. It was later approved in November 2021.
    • In November 2021, the IND application for JS112 (Aurora A inhibitor) was accepted by the NMPA. It was later approved in February 2022.
    • In December 2021, the IND application for JS107 (recombinant humanized anti- Claudin18.2 monoclonal antibody – MMAE conjugate) was accepted by the NMPA. It was later approved in March 2022.
    • In December 2021, the IND application for JS001sc (a subcutaneous injection formulation developed on the basis of toripalimab) was accepted by the NMPA. It was later approved in March 2022.
    • In December 2021, the sNDA of toripalimab in combination with standard first-line chemotherapy for untreated, driver-negative advanced non-small cell lung cancer (“NSCLC”) was accepted by the NMPA.
    • In January 2022, based on the Exclusive License and Commercialization Agreement Junshi Biosciences entered into with Coherus in February 2021, Coherus initiated the procedure for exercising the option of TAB006/JS006, one of the option programs, to be licensed to develop TAB006/JS006 or any product containing TAB006/JS006 in the Coherus Territory for the treatment or prevention of human disease. Coherus will pay Junshi a one-time execution fee of US$35 million and cumulative milestone payment of up to US$255 million upon reaching the corresponding milestones, plus 18% royalty on the annual net sales of any product that contains TAB006/JS006 in the Coherus Territory.
    • In February 2022, the dosing of the first patient was completed in the Phase III clinical trial of toripalimab in combination with standard chemotherapy as the adjuvant treatment after radical resection of gastric or esophagogastric junction adenocarcinoma (JUPITER-15 study, NCT05180734).
    • In March 2022, the marketing of adalimumab (Commercial name in China: Junmaikang) for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis was approved by the NMPA.
    • In March 2022, the IND application for JS105 (PI3K-α inhibitor) jointly developed by the company and Risen (Suzhou) Biosciences Co., Ltd. was accepted by the NMPA.
    • In March 2022, Junshi Biosciences entered into a licensing and cooperation agreement with Wigen Biomedicine to introduce four small molecule anti-tumor drugs, namely JS120 (second-generation irreversible IDH1 inhibitor), JS121 (SHP2 inhibitor), JS122 (second-generation irreversible FGFR2 selective inhibitor) and JS123 (ATR inhibitor), thus further enriching the pipeline in cancer therapy.
  • Tackling the COVID-19 Challenge: In the face of the novel coronavirus pandemic (“COVID-19”), Junshi Biosciences responded swiftly and cooperated with domestic and foreign scientific research institutions and enterprises to jointly develop a variety of drug candidates for the treatment of the COVID-19, and took the initiative to undertake the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. The company has made significant progress.
    • Etesevimab (JS016/LY-CoV016): In early 2020, Junshi Biosciences jointly developed etesevimab with the Institute of Microbiology, Chinese Academy of Sciences (the “IMCAS”). Lilly licensed the rights and interests of etesevimab from the Company outside the greater China territories (including mainland China, the Hong Kong Special Administrative Region, the Macao Special Administrative Region and the Taiwan region), and Junshi continued to lead the development of the drug in the greater China territories. In February 2021, the FDA granted Lilly the Emergency Use Authorization (“EUA”) for etesevimab 1,400 mg and bamlanivimab (LY-CoV555) 700 mg together (the “dual antibody therapy”) for the treatment of patients with mild to moderate COVID-19 aged 12 and above who were at high risk for progressing to severe COVID-19 and/or hospitalization. In September 2021, the FDA granted the EUA for the dual antibody therapy for the application of treatment for high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination, and have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in an institutional setting, including a nursing home or prison. In December 2021, the scope of EUA was newly extended to include treatment and post-exposure prevention of mild to moderate COVID-19 for specific high-risk pediatric populations (from infant to child aged under 12). As of the end of 2021, the dual antibody therapy has been granted the EUA in more than 15 countries and regions around the world, and more than 700,000 patients have received the dual antibody therapy or bamlanivimab treatment, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths during the worst period of the pandemic.
    • VV116 (JT001): In September 2021, JunTop Biosciences, a subsidiary of the Company, partnered with Suzhou Vigonvita Biomedical Co., Ltd. (“Vigonvita”) to jointly undertake the clinical development and commercialization of VV116, an oral nucleoside anti-SARS-CoV-2 drug, in the collaboration territory, being the whole world except for the following four territories, namely the five Central Asian countries, Russia, North Africa and the Middle East. VV116 was approved for the treatment of moderate to severe COVID-19 patients in Uzbekistan (not within the collaboration territory) in late 2021. The Company was conducting an international multi-center, randomized, double-blind, controlled phase III clinical study to evaluate the efficacy and safety of VV116 versus standard treatments in subjects with moderate to severe COVID-19. The enrollment and dosing of the first patient has been completed. In addition, for mild to moderate COVID-19, the Company has also initiated an international multi-center, double- blind, randomized, placebo-controlled, Phase II/III clinical study (NCT05242042) to evaluate the efficacy, safety and pharmacokinetics of VV116 for early treatment of patients with mild to moderate COVID-19. The study has completed the enrollment and dosing of the first patient in Shanghai Public Health Clinical Center and is in progress in multiple centers around the world.
    • VV993 (JT003): In January 2022, JunTop Biosciences partnered with Vigonvita to jointly undertake the research, production and commercialization of VV993, a new oral anti-SARS-CoV-2 drug candidate targeting 3CL protease, in the collaboration territory.
  • Platform Expansion: Apart from developing drug candidates on Junshi Biosciences’ own technology platforms, the company has also actively collaborated with outstanding domestic and overseas biotechnology companies to further expand its product pipeline, deploy the next-generation innovative drug technology platform and enrich drug combination therapies.
    • In July 2021, Junshi Biosciences and Immorna (Hangzhou) Biotechnology Co., Ltd. (“Immorna”) entered into an agreement to start a JV, which will mainly engage in the R&D, clinical research, application for approval, production and commercialization of product development projects in the fields of tumors, infectious diseases, rare diseases and other diseases agreed by both parties on the mRNA technology platform globally. The jointly formed company will be owned 50% by the Company and 50% by Immorna upon its formation. The establishment of the jointly formed company can complement each party’s technological advantages, capitalize the strengths of the mRNA general platform technology in tumor immunotherapy, infectious disease prevention and other fields in a more efficient manner, and continuously explore new directions of application.
  • Update on commercialization
    • Additional Indications included in NDRL: Toripalimab continued to be included in Category B in the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021 Edition) (“NRDL”)). It was approved for two additional indications of the treatment of patients with recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy as well as the treatment of patients with locally advanced or metastatic UC who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy, and became the only anti-PD-1 monoclonal antibody used in the treatment of melanoma and nasopharyngeal cancer in the NRDL, which filled the gaps in immunotherapy for patients with advanced NPC and non-selective patients with advanced UC in the NRDL, and became the only anti-PD-1 monoclonal antibody used in the treatment of melanoma and nasopharyngeal cancer in the NRDL.
    • Toripalimab achieved sales of RMB412 million in 2021. After the official implementation of the 2020 NRDL in March 2021, the terminal pricing of toripalimab dropped by over 60% compared to the initial pricing in 2020. Moreover, after the continued inclusion in the 2021 NRDL and further price reduction of toripalimab at the end of 2021, the company compensated the price difference for the entire inventory of the distributors, which also had a certain impact on the recognition of product revenue for the current period. 2021 was also a relatively turbulent year for the commercialization team. The team underwent several rounds of adjustment in regards to commercialization managers and internal marketers. In November 2021, the Board of Directors of the Company appoint Mr. Cong Li as a co-chief executive officer to be fully responsible for commercialization-related activities. All necessary adjustments to the commercialization team have been made, and Mr. Cong Li has completed the establishment and restoration of the marketing regional team and also supplemented the core market personnel. In December 2021, after friendly negotiation, the company withdrew the promotion rights agreed in the agreement with AstraZeneca Pharmaceutical Co., Ltd., (“AstraZeneca Pharmaceutical”) that the company’s commercialization team would be independently responsible for all promotion activities of toripalimab in mainland China. Through urban commercial insurance across the country, out-of-pocket expenses on the indications of toripalimab included in the NRDL were entitled to supplementary reimbursement under the NRDL in 102 cities, and the newly approved first-line treatment for nasopharyngeal cancer indication in November 2021 has entered the medical insurance catalogues in 11 cities, for which supplementary medical insurance could be obtained in 51 cities, thus reducing the burden on patients. After the recovery of toripalimab outsourced indications and promotion right in wide market from AstraZeneca Pharmaceutical, and the inclusion of toripalimab in the NRDL for treatment of melanoma, nasopharyngeal and urothelial cancer, commercial team members have also regained their confidence. The sales activities of toripalimab in the domestic market bounced back to normal levels. A series of marketing campaigns had commenced, aiming to reshape the market image of the company and toripalimab. Junshi Biosciences is optimistic that it can gain market share in those tumor types that had been included in NRDL indications. More large indications of toripalimab have completed the Phase III registration clinical trials and entered the commercial approval stage. With the gradual realization of the prospective layout advantages of multi-indication perioperative clinical research as well as the upgrade in production capacity of commercial production batches of the company’s production base, Junshi Biosciences is very optimistic about the long-term commercial opportunity of toripalimab in the domestic market.
    • In March 2022, Shanghai Junshi Biotechnology Co., Ltd. (“Junshi Biotechnology”), the company’s wholly-owned subsidiary, passed the drug GMP compliance inspection, indicating that the production base in Lingang, Shanghai (the “Lingang Production Base”) fully met the conditions to formally produce commercial batches of toripalimab. The Lingang Production Base in Shanghai was constructed in accordance with the cGMP standard, with a production capacity of 30,000L in the first phase of the project. By virtue of economies of scale, the expansion of production capacity brought by the Lingang Production Base in Shanghai will enable the Company to gain the advantage of a more competitive production cost.
  • Financing activity highlights: In order to optimize the capital structure, focus more on the development of the principal business, improve operating efficiency, increase investment in R&D and better serve technological innovation, Junshi Biosciences has carried out the following financing activities:
    • In June 2021, the company successfully allotted and issued an aggregate of 36,549,200 new H Shares at the placing price of HK$70.18 per H Share to no less than six placees (the “Placing”). The net proceeds from the Placing were approximately RMB2,105 million. The proceeds from the Placing were intended to be used toward the R&D of drugs and pipeline expansion, expansion of the commercialization team, domestic and overseas investment, mergers and acquisitions, and business development, and general corporate purposes.
    • In December 2021, JunTop Biosciences implemented the series A financing, with 14 series A investors subscribing for the new registered capital of JunTop Biosciences at a total consideration of RMB1.275 billion. The proceeds will be used to finance the R&D and production of vaccine and anti-infective drug pipelines of JunTop Biosciences.
    • In March 2022, the Board of Directors approved a proposal to issue about 70 million A Shares to target subscribers under the General Mandate. The proceeds are expected to be approximately RMB3.98 billion, which will be used for R&D projects of innovative drugs and company headquarters and R&D base project. The issuance is still subject to the approval of shareholders of the Company (the “Shareholders”) at the EGM, the approval of the Shanghai Stock Exchange and the approval of registration from the China Securities Regulatory Commission.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (“EUA”) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has over 2,800 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com 
+ 86 021-2250 0300

Goby Global
Bob Ai
bai@gobyglobal.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Critics see ‘scary reality’ as China touts Xinjiang police high case clearance rates

Police in China’s far-western Xinjiang region ranked first in the country in 2021 for solving all homicide cases, while the region’s High People’s Court was hailed as a model for concluding the greatest number of cases last year, according to a Chinese state media report that prompted political and legal analysts outside the country to raise questions about the results.

Xinjiang’s Public Security Bureau achieved a 100% resolution rate in current murder cases for six consecutive years, ranking first in the country, while the region’s High People’s Court handled 17,600 cases related to people’s livelihoods in 2021, the highest number in all of China, said the March 25 report by the China News Service in Urumqi (in Chinese, Wulumuqi), Xinjiang’s capital.

“For six consecutive years, the police detection of number of homicides in Xinjiang has increased to 100%, with the number of homicides in Xinjiang falling to its lowest level in history, with the highest number of homicides detected in the history,” the report said.

The Xinjiang Public Security Bureau (PSB) has in recent years launched a mechanism of average people “collectively assisting the Xinjiang Uyghur Autonomous Region [XUAR] public security bureau’s criminal investigation team in investigating major cases,” it said.

The report also stated that the PSB had implemented a “one file per case” standard, and through gathering complete past records of crimes, were able to find murderers from cases dating back 20 years.

Xinjiang police have been using a “one tactic per person, one plan per person, one measure per person” system for detecting criminals by using advanced technology and information, and identifying and analyzing suspicious activities, the report said.

Ilshat Hassan Kokbore, a political analyst based in U.S., said that such Chinese reports are unreliable because the Chinese police’s handling of cases is “completely obscure.”

“We cannot just trust the numbers provided by the Chinese government in their reports,” he told RFA. “This is always the case because Chinese police statistics or figures are unreliable.”

“Second, they don’t disclose their records,” said Kokbore, who is also vice chairman of the Executive Committee of the World Uyghur Congress. “They always keep it all the evidence undisclosed. No one can question the credibility of their findings or evidence. To sum up they detect their cases in the dark, not in the open.”

Chinese human rights activist and lawyer Teng Biao said that while the Chinese police in Xinjiang did not disclose the number of cases they have detected, the fact that they ranked first in the country is concerning.

“[Xinjiang police] saying that in six years they have raised the case clearance rate to 100% and reduced the crime rate to its historic low has a scary reality behind it,” he told RFA.

Setting up internment camps and installing high-tech surveillance cameras everywhere has helped in authorities’ efforts to expose “crimes” and to reduce the crime rate, Teng said.

“In the Chinese judiciary, on the other hand, the power of the police is greater than the power of the judge and the prosecutor,” he said. “If the police suspect someone, the judge and prosecutor will also convict him.”

Teng noted that the Xinjiang police were able to report a 100% case clearance rate and rank first in China because police routinely use torture to obtain confessions, which then are included in court verdicts.

“In China, the law enforcement agencies have a lot of power, the judiciary is not independent, and there are a lot of wrongdoing and murder cases that have been suppressed because of the lack of freedom of the press,” Teng said.

‘Justice in today’s world’

Speaking about the Xinjiang High People’s Court’s achievement, Teng told RFA that judicial standards should be fair, and pursuing speedy outcomes should not be priority.

“Chasing speed is a sign that China has turned its own judicial system into something else. It is incompatible with the idea of justice in today’s world,” he said.

Officials have conducted a major shakeup of judges and prosecutors who work in the Xinjiang judiciary, according to a March 28 report by the Bingtuan News Network, run by the Xinjiang Production and Construction Corps (XPCC).

A state-owned economic and paramilitary organization, the XPCC, also known as the Bingtuan, has been sanctioned by the U.S. for its involvement in human rights violations against Uyghurs.

On Monday, the Standing Committee of the XUAR’s People’s Congress issued a list of more than 120 officials who have been dismissed or appointed to serve in the region’s courts.

Experts say that it is rare for so many judges and prosecutors to be replaced in Xinjiang at the same time, but that the Chinese government is likely refreshing the judiciary and prosecutors as it prepares for an upcoming visit by a U.N. delegation led by Michelle Bachelet, the U.N. high commissioner for human rights, to Xinjiang.

Bachelet announced earlier in March that she had reached an agreement with the Chinese government for a visit “foreseen to take place in May” to China, including the turbulent Xinjiang region.

Her office is under pressure from rights activists to issue an overdue report on serious rights violations by Chinese authorities targeting Uyghurs and other Turkic communities in the XUAR.

Up to 1.8 million Uyghurs and others have been held in a vast network of internment camps operated by the Chinese government under the pretext of preventing religious extremism and terrorism among the mostly Muslim groups.

“In preparation for the U.N. rights chief visit in the region, the Chinese government may have removed the politically unreliable judges and prosecutors and replaced them with judges and prosecutors loyal to the Chinese Communist Party,” Teng said.

Reported and Translated by RFA’s Uyghur Service. Written in English by Roseanne Gerin.

‘Spying’ trial of Australian national, state TV anchor Cheng Lei held in secret

Australian national and Chinese state TV anchor Cheng Lei stood trial behind closed doors at a Beijing court on Thursday for alleged breaches of the national security law.

Cheng was detained on suspicion of “spying” in August 2020, and has been held incommunicado for more than 18 months since.

She stood trial at the Beijing No. 2 Intermediate People’s Court on Thursday, amid tight security, but accompanied by a lawyer, according to an Australian diplomat at the scene.

Australian ambassador to China Graham Fletcher said he was denied permission to sit in the public gallery for the trial, on the grounds that the case “involved state secrets.”

The refusal came despite a public request from Australian foreign minister Marise Payne, who called on Beijing to allow diplomats to observe the trial and observe basic standards of fairness, procedural justice and humane treatment.

Fletcher told reporters he was concerned about the outcome for Cheng.

Beijing-based criminal lawyer Zhang Dongshuo said the harshness of Cheng’s sentence — Chinese courts rarely acquit defendants outright — would likely depend on how sensitive the “secrets” involved were deemed to be.

“If it is a question of more than one instance, for example, sentencing would be very different if there were more than 10 or less than 10 instances,” Zhang said. “Whether it involved the highest-level of classified information, what they call ‘top secret,’ or a lower level [also affects the outcome].”

He said Cheng’s Australian passport is unlikely to help her much.

“Nationality and identity are generally not considered in sentencing, but in some special cases, it could be affected by matters of national defense, foreign affairs and other matters, and special consideration may be given by the court,” Zhang said.

Currently, sentencing for those found guilty of “illegally providing state secrets overseas” ranges between five and 10 years’ imprisonment, but lighter sentences have also been given, he said.

If Cheng was seen as “cooperative,” for example, if she “confessed” to the charges and pleaded guilty, she could be released soon after the trial.

“This possibility certainly exists,” Zhang said. “If the number and level of state secrets in Cheng Lei’s case aren’t high, then she could receive a fairly light sentence with time already served deducted.”

But he said there was no guarantee, in the absence of further information about the charges faced by Cheng.

Feng Chongyi, a professor of political science at the University of Technology Sydney, said the existence of any “confession” was the most important factor, however.

“This is very important,” Feng said. “This is the scary part of the Chinese criminal law. It requires the person to plead guilty, and it depends on your attitude in making a confession.”

“Cheng Lei is a mother of two children. That would make it easier to negotiate with the Chinese authorities and to reach a compromise,” he said.

Bloomberg employee

Meanwhile, little has been heard of Bloomberg News employee Haze Fan, who was taken away by state security police in December 2020 on suspicion of “endangering national security.”

Chinese authorities have only said that investigation into her case is still ongoing.

Both Fan and Cheng had been friends, helping to collect donations of medical supplies to aid front-line medical workers in the early days of the COVID-19 pandemic in Wuhan, according to information publicly available on Facebook.

The New York-based Committee to Protect Journalists (CPJ) has called for Fan’s immediate and unconditional release, saying the allegations against her have no credibility.

Cheng, 47, was born in Hunan and moved to Australia with her parents as a child. She once worked as an anchor on China Global Television News (CGTN), the international arm of CCTV.

She was detained in August 2020 and formally arrested in February 2021.

Cheng’s detention came amid increasingly strained ties between Beijing and Canberra, which is taking steps to limit the Chinese Communist Party (CCP)’s propaganda outreach in the country, and which has barred Chinese telecoms giant Huawei from bidding for 5G mobile contracts.

Risks of reporting

While foreign journalists have long faced challenging conditions under CCP rule, now they are also dealing with growing hostility and intimidation, including online stalking, smear campaigns, hacking and visa denials, the Foreign Correspondents’ Club of China (FCCC) said in its annual report in February 2022.

More than 60 percent of respondents had been obstructed by police or officials last year, while almost all journalists who went to Xinjiang were visible followed throughout their trips, while more than a quarter said their sources had been detained, harassed or questioned more than once following interviews.

There is also a growing legal threat for journalists working in China, with the authorities encouraging a spate of lawsuits or the threat of legal action against foreign journalists, typically filed by sources long after they have explicitly agreed to be interviewed, the report said.

It said “state-backed attacks” including online trolling of foreign journalists is also on the increase.

Translated and edited by Luisetta Mudie.

Vista strengthens its global and U.S. leadership with the acquisition of Jet Edge’s platform

Vista acquisition — Jet Edge

Jet Edge, hangar

VISTA STRENGTHENS ITS GLOBAL AND U.S. LEADERSHIP
WITH THE ACQUISITION OF JET EDGE’S PLATFORM

  • Acquisition of the private aviation services platform of Jet Edge, the fastest-growing North American charter operator, significantly scales up Vista’s U.S. presence;
  • The acquisition provides additional flexibility, infrastructure and scale to support its growing client base and demand across North America;
  • Vista clients to access 100 additional aircraft including the largest charter fleet of Gulfstream jets in the U.S.;
  • Jet Edge Reserve Members and Aircraft Owners will benefit significantly from Vista’s broader global fleet and platform;
  • Bill PapariellaJet Edge CEO, to join Vista’s executive team as Chief Business Officer and Jet Edge’s experienced management team remaining in place, in accordance with U.S. DOT requirements;
  • Transaction expected to complete in the second quarter of 2022, subject to customary closing conditions;
  • Follows the recent successful integrations of Red Wing Aviation, Apollo Jets and Talon Air into Vista’s ecosystem and AIR HAMBURG acquisition announcement.
Vista acquisition — Jet Edge

Jet Edge, tails

Dubai, March 31, 2022: Vista Global Holding (Vista), the world’s leading private aviation group, announces that it has entered into an agreement to acquire the private aviation services platform of Jet Edge, the fastest-growing North American charter operator.

Founded in 2011, Jet Edge is an integrated charter, management and brokerage platform and a leading U.S. provider of large cabin and super-midsize private jet charter and aircraft management services. At the time of this announcement, Jet Edge has a run rate of 60,000+ yearly flight hours, exclusively in the large-cabin and super-midsize category. Following the completion of the transaction in Q2 2022 Vista expects its fleet availability to expand to approximately 350 aircraft.

The move highlights Vista’s continued investment into the U.S., the largest and fastest-growing region, and follows the recent announcement of a deal with AIR HAMBURG, balancing its fleet to respond to the significant demand it experienced across the two the largest aviation markets.

Thomas Flohr, Vista’s Founder and Chairman, said: “Vista’s commitment is to provide the most comprehensive range of flying solutions in private aviation. Today’s announcement brings significant value to our clients, with access to a further 100 aircraft, expanding our fleet at a time of unprecedented demand for business aviation services.

“Our vision is to provide the best services, anytime and anywhere, for every client. Bringing Jet Edge, the fastest-growing large-cabin and super-mid on demand company in the U.S., into the Group scales up our presence in North America, giving Vista the opportunity to turbocharge growth in the most dynamic business aviation market. It also means expanding our offering and presenting our Members with the chance to fly on the largest fleet of Gulfstream aircraft available for charter.

“I am also delighted to welcome Bill Papariella to Vista’s executive team as Chief Business Officer. As we continue to revolutionize the private aviation market, we are ready to integrate the extensive expertise of our new colleagues across the whole Jet Edge family. This acquisition is the latest example of Vista’s ability to capitalize on key opportunities in the highly fragmented and fast-growing business aviation world.”

Bill PapariellaJet Edge’s CEO, said: “Vista is, without a doubt, the best operational platform in private aviation, and it aligns with our company’s promise of safe operational service and a superior flight experience. Thanks to industry-leading technology, the most coveted global fleet and the personal expertise of everyone on the team, this merger takes the Jet Edge platform to the next level overnight. Our Members will now get access to an extensive global fleet, programs, services and a network able to fly them anywhere in the world. Our Aircraft Owners will be able to take advantage of the enormous charter demand, global infrastructure and procurement advantages that Vista generates via its iconic brands VistaJet and XO.

“We are proud of the personal relationships we have built with each one of our Reserve Members and our Aircraft Owners — this has been the main driver behind our tremendous growth in the past few years, at a time when aircraft availability was at a historical minimum. We cannot wait to be able to offer them additional value through our integration with Vista. I couldn’t be more proud of the hard work of our teams, and I am excited about our long future together as a Vista company”.

The values of maximum safety and customer service excellence are critical for both organizations and the acquisition of the private aviation services platform of Jet Edge is the latest chapter of a longstanding partnership between the company and XO, VistaJet and Apollo Jets. The acquisition brings together two long-established companies with the shared vision of delivering the best flying solutions and experiences to their Members.

The merger is the latest step in Vista’s relentless transformation of the highly fragmented business aviation ecosystem. Vista’s maintenance services in North America will expand with the acquisition of Jet Edge’s Part 145 maintenance facility, located strategically on the West Coast. It will provide a full suite of maintenance services to a wide range of aircraft types, augmenting the maintenance capacity across the U.S. and securing better access to parts. The acquisition will also provide two branded lounges in Van Nuys and Teterboro, ready to welcome all guests departing from these strategic terminals.

In accord with U.S. DOT requirements, Vista will acquire Jet Edge aircraft, hospitality and maintenance facilities, while its U.S. strategic operating partner XOJET Aviation will acquire a majority stake of the Part 135 certificates of Jet Select and Western Air Charter.

— Ends —

About Vista
Vista Global Holding’s (Vista) subsidiaries provide worldwide business flight services. A global group headquartered at the DIFC in Dubai, Vista integrates a unique portfolio of companies offering asset-free services to cover all key aspects of business aviation: guaranteed and on demand global flight coverage; subscription and Membership solutions; and cutting-edge mobility technology. The Group’s mission is to lead the change to provide clients with the most advanced flying services at the very best value, anytime, anywhere around the world. Vista’s knowledge and understanding of all facets of the industry deliver the best end-to-end offering and technology to all business aviation clients through its VistaJet and XO branded services and duly licensed carriers. Vista is not a direct air carrier and does not operate or charter flights.
More Vista information and news at www.vistaglobal.com

About Jet Edge
Jet Edge is a leader in full-service global private aviation. As an integrated super-midsize and large cabin management operator and maintenance provider, Jet Edge services aircraft owners and charter flyers with a world-class operational platform. Jet Edge extends individual clients and corporations 365-day-a-year access to one of the most well-appointed aircraft fleets in the world. Backed by award-winning safety programs and overseen by a leadership team with wide-ranging experience in commercial and private aviation operations and management, Jet Edge delivers excellence in aircraft management, charter management, on-demand charter, aircraft sales, and maintenance. More information can be found at www.flyjetedge.com

Contacts
press@vistaglobal.com

Vista Global Holding Limited (“Vista”) does not own or operate any aircraft. All flights are performed by FAA-licensed/DOT-registered EASA or U.S. certified Vista group direct air carriers and/or partner operators. Vista holds non-controlling minority stakes in XOJET Aviation, GMJ Air Shuttle, Red Wing Aviation and Talon Air.

Attachments